BGLC Pengajuan SEC - BioNexus Gene Lab Corp.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1737523

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioNexus Gene Lab Corp.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 18, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp.
August 18, 2025	EX-10.8	Form of Non-Qualified Stock Option Agreement EXHIBIT 10.8 BIONEXUS GENE LAB CORP. FORM OF NON‑QUALIFIED STOCK OPTION AGREEMENT This Non‑Qualified Stock Option Agreement (this “Agreement”) is made as of the Grant Date specified in Exhibit A (Grant Summary) by and between BioNexus Gene Lab Corp., a Wyoming corporation (the “Company”), and the individual identified in Exhibit A (the “Optionee”), pursuant to and in furtherance of a standalone co
August 14, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2025 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit A-28-7, Tower A, Menara UOA Bangsar, No. 5 Jln
July 30, 2025	EX-99.1	BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology Kuala Lumpur, Malaysia – July 30th, 2025 – BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company (“Fidelion”) today announced the signing of a term sheet for a strategic, cross‑equity
July 30, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp
June 23, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Commi
June 23, 2025	EX-10.7	The Service Contract between the Company and Ms. Chong Set Fui (Angeline) EXHIBIT 10.7 MRNA Scientific Sdn Bhd A-28-07 Menara UOA Bangsar No. 5 Jalan Bangsar Utama 1 Kuala Lumpur, Malaysia 59000 PRIVATE & CONFIDENTIAL [BY HAND] 17 June 2025 Chong Set Fui (Angeline) Dear Mrs. Chong, LETTER OF EMPLOYMENT – CHIEF FINANCIAL OFFICER We are pleased to offer you employment in MRNA SCIENTIFIC SDN BHD (the “Company”) according to the following terms and conditions: 1. JOB TITLE
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp.
April 30, 2025	EX-99.1	BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness Kuala Lumpur, Malaysia - April 30, 2025 - BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Mark
April 30, 2025	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incor
April 29, 2025	EX-97	Policy Relating to Recovery of Erroneously Awarded Compensation* EXHIBIT 97 BIONEXUS GENE LAB CORP. (the “Company”) Policy on Recovery of Erroneously Awarded Compensation ("Clawback Policy") 1. Purpose This Policy is established to comply with Section 10D of the Securities Exchange Act of 1934 and Rule 10D-1 thereunder, as well as Nasdaq Listing Rule 5608. The Policy provides for the recovery of certain incentive-based compensation awarded to current and former
April 29, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 FORM 10-K/A (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.
April 15, 2025	EX-3.7	Articles of Amendment filed with the Wyoming Secretary of State on April 1, 2025. EXHIBIT 3.7
April 15, 2025	EX-10.4	Director Offer Letter by and between the Registrant and Muhammad Azrul bin Abdul Hamid EXHIBIT 10.4 March 26, 2024 Re: Director Offer Letter – Muhammad Azrul bin Abdul Hamid Dear Mr. Muhammad Azrul bin Abdul Hamid: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward to your participation as a Dir
April 15, 2025	EX-10.5	Director Offer Letter by and between the Registrant and Jook Yuen Low EXHIBIT 10.5 November 5, 2024 Re: Director Offer Letter – Jook Yuen Low Dear Ms. Jook Yuen Low: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward to your participation as a Director in the Company. Should you
April 15, 2025	EX-3.2	Bylaws of the Registrant, as currently in effect EXHIBIT 3.2 BYLAWS OF BIONEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require. Section 1.2. Registe
April 15, 2025	EX-10.3	Director Offer Letter by and between the Registrant and Su-Leng Tan Lee EXHIBIT 10.3 March 26, 2024 Re: Director Offer Letter – Su-Leng Tan Lee Dear Mr. Tan Lee: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward to your participation as a Director in the Company. Should you choos
April 15, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41750 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
April 15, 2025	EX-3.6	Articles of Amendment filed with the Wyoming Secretary of State on February 11, 2025. EXHIBIT 3.6
April 15, 2025	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21 Subsidiaries MRNA Scientific Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation
April 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp
April 3, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp
April 3, 2025	EX-3.7	Articles of Amendment filed with the Wyoming Secretary of State on April 1, 2025. EXHIBIT 3.7
March 31, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit A-28-7, Tower A, Menara UOA Bangsar, No. 5
March 25, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2025. BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Inco
March 7, 2025	EX-99.1	BioNexus Gene Lab Corp and EXHIBIT 99.1 BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy March 7, 2025 – Kuala Lumpur, Malaysia – BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. ML Tech is an AI-driven wea
March 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2025. BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incor
March 5, 2025	EX-99.1	BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper Kuala Lumpur, Malaysia – March 5, 2025 – BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in technology and healthcare, is pleased to announce that its Board of Directors has formally approved the Company’s new Eth
March 5, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp
February 28, 2025	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def
February 27, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
February 14, 2025	EX-3.6	Articles of Amendment filed with the Wyoming Secretary of State on February 11, 2025. EXHIBIT 3.6
February 14, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (C
February 10, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
January 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (C
November 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp.
November 14, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2024 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit A-28-7, Tower A, Menara UOA Bangsar, No.
November 8, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Co
October 15, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com
October 10, 2024	8-K	Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com
September 25, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 25, 2024 (September 23, 2024). BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commiss
September 25, 2024	EX-99.1	BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. EXHIBIT 99.1 Press Release For Immediate Release BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. Kuala Lumpur, Malaysia – September 25, 2024 – MRNA Scientific Sdn. Bhd. (“MRNA”), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), and Protech Builders Sdn. Bhd. (“Protech”), a leading mechanical and electrical
September 25, 2024	EX-10.1	The Teaming Agreement between MRNA Scientific Sdn. Bhd. and Protech Builders Sdn. Bhd. for Biogas Plant Development, dated September 23, 2024. EXHIBIT 10.1 Teaming Agreement between MRNA Scientific Sdn. Bhd. and Protech Builders Sdn. Bhd. for Biogas Plant Development This Teaming Agreement (“Agreement”) is made on September 23, 2024 between: ● MRNA Scientific Sdn. Bhd. (“MRNA Scientific”, Co. 201501013741), a company incorporated in Malaysia, with its principal office at A-28-07 Menara UOA Bangsar, 5 Jalan Bangsar Utama 1, Kuala Lumpur 1
September 18, 2024	EX-99.1	1 EXHIBIT 99.1 BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd. KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) - BioNexus Gene Lab Corp.(Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. (“MRNA Scientific”),
September 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 (Septe UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 (September 14, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdictio
September 16, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
September 12, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 (September 11, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdictio
September 12, 2024	EX-99.1	2 EXHIBIT 99.1 BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production Kuala Lumpur, Malaysia – September 11, 2024 – BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximate
September 12, 2024	EX-99.2	BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions EXHIBIT 99.2 BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions Kuala Lumpur, Malaysia – September 12, 2024 – BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing
September 6, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
September 5, 2024	EX-3.1	The Amended and Restated Bylaws EXHIBIT 3.1 BYLAWS OF BIO NEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require. Section 1.2. Regist
September 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 (Septem UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 (September 4, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction
August 28, 2024	EX-99.1	BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd EXHIBIT 99.1 BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd KUALA LUMPUR, August 27th, 2024 – BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia
August 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com
August 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com
August 26, 2024	EX-10.1	Shareholders Agreement and Term Sheet dated August 23, 2024 EXHIBIT 10.1 THIS SHAREHOLDERS AGREEMENT is made on 23rd August 2024 AMONGST (1) THE EXISTING SHAREHOLDERS whose names and particulars are as set out in Schedule 1; (2) THE CROWDFUNDING DIRECT SHAREHOLDERS whose names and particulars are set out in Schedule 2; (3) THE NOMINEE whose name and particulars are set out in Schedule 3; (“the Existing Shareholders, the Crowdfunding Direct Shareholders and
August 26, 2024	EX-99.1	BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd EXHIBIT 99.1 BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd KUALA LUMPUR, August 26th, 2024 – BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysi
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp.
July 5, 2024	EX-10.1	Amendment to the Service Contract between the Company and Mr. Su-Leng Tan Lee dated June 30, 2024 EXHIBIT 10.1 Date: June 30, 2024 Mr. Su-Leng Tan Lee C2-2-8 Megan Phoenix Off Jalan Cheras Kuala Lumpur, Malaysia Dear Mr. Tan Lee, Re: Amendment to Service Contract, recognition as Chief Executive Officer and Acting Chief Financial Officer We are pleased to extend this letter of offer to you, amending your current service contract dated August 15, 2023. This amendment recognizes your role as Chie
July 5, 2024	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 (March 26, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other j
May 31, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.1 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.
May 31, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.
May 31, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.
May 31, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.1 FORM 10-K/A (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.
May 31, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 2 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.
May 23, 2024	CORRESP	Explanatory Note May 23, 2024 Securities and Exchange Commission Division of Corporate Finance Washington DC 20549 Re: Comment Letter from Staff of Securities and Exchange Commission Dated May 6, 2022 BioNexus Gene Lab Corp.
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
May 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2024 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File No.)
April 18, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Com
April 18, 2024	EX-99.1	6 EXHIBIT 99.1 BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare FOR IMMEDIATE RELEASE Kuala Lumpur, Malaysia - April 18, 2024 — BioNexus Gene Lab Corporation (NASDAQ: BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned
April 16, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-269753 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
April 16, 2024	EX-21	List of Subsidiaries of the Registrant EXHIBIT 21 Subsidiaries MRNA Scientific Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation
April 1, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Com
March 28, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit 02, Level 10 Tower B, Avenue 3, The Vertic
March 26, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
February 29, 2024	DEF 14C	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by R
January 26, 2024	PRE 14C	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by R
January 23, 2024	SC 13G	US0906282076 / BIONEXUS GENE LAB CORP / Erayak Power Solution Group Inc. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIONEXUS GENE LAB CORP COMMON STOCK 090628207 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remainder
January 17, 2024	EX-99.1	Joint Filing Agreement, by and between the Reporting Persons. EX-99.1 2 bglcex991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock, no par value per share, of BioNexus Gene La
January 17, 2024	SC 13D	US0906282076 / BIONEXUS GENE LAB CORP / Lai Soo Kow - SC 13D Activist Investment SC 13D 1 bglcsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BioNexus Gene Lab Corp. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 090628207 (CUSIP Number) Su-Leng (Sam) Tan Lee Unit 02, Level 10 Tower B, Avenue 3, The Vertical Business Suite II Bangsar Sou
November 20, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
November 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit 02, Level 10 Tower B, Avenue 3, The Verti
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File
November 3, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission Fil
October 30, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation
October 17, 2023	SC 13G	BGLC / BioNexus Gene Lab Corp / Wong Chan Chong - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BioNexus Gene Lab Corp. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 090628207 (CUSIP Number) July 19, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
October 16, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission Fil
October 11, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission File
September 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission Fi
August 16, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
August 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing SEC File Number 333-201360 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing SEC File Number 333-201360 ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit 02, Level 10 Tower
July 24, 2023	EX-99.1	1 EXHIBIT 99.1 BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market KUALA LUMPUR, Malaysia, July 20, 2023 (GlobeNewswire) - BioNexus Gene Lab Corp. (“BioNexus” or the “Company”), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liqui
July 24, 2023	EX-4.1	Form of Underwriter’s Warrants EXHIBIT 4.1 Underwriter’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING: (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO ANYONE OTHER THAN OFFICERS
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File No.
July 24, 2023	EX-3.1	Amended and Restated Bylaws EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF BIONEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require.
July 24, 2023	EX-99.2	1 EXHIBIT 99.2 BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market KUALA LUMPUR, Malaysia, July 24, 2023 (GlobeNewswire) - BioNexus Gene Lab Corp. (“BioNexus” or the “Company”) (Nasdaq: BGLC), an emerging company in the business of selling chemical raw materials in the Southeast Asia region a
July 24, 2023	EX-1.1	Underwriting Agreement by and between BioNexus Gene Lab Corp. and Network 1 Financial Securities, Inc. dated July 20, 2023 EXHIBIT 1.1 UNDERWRITING AGREEMENT July 20, 2023 Network 1 Financial Securities, Inc. 2 Bridge Ave - Building 2 Suite 241 Red Bank, NJ 07701 Ladies and Gentlemen: Bionexus Gene Lab Corp., a Wyoming company (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Network 1 Financial Securities, Inc. (the “Underwriter”) an aggregate of 1
July 21, 2023	424B4	BIONEXUS GENE LAB CORP. 1,250,000 Shares of Common Stock Filed pursuant to Rule 424(b)(4) Registration No. 333-269753 PROSPECTUS BIONEXUS GENE LAB CORP. 1,250,000 Shares of Common Stock We are offering up to an aggregate of 1,250,000 shares of our common stock, no par value per share, of BioNexus Gene Lab Corp, a Wyoming corporation, on a firm commitment basis. The initial public offering price of our common stock is $4.00 per share. Prior to this offer
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2023 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File No.
July 20, 2023	EX-3.1	Article of Amendment dated March 29, 2023 EXHIBIT 3.1
July 20, 2023	EX-3.2	Article of Amendment dated June 5, 2023 EXHIBIT 3.2
July 19, 2023	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No
July 17, 2023	EX-4.2	Form of Representative’s Warrant EXHIBIT 4.2 Representative’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING: (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO ANYONE OTHER THAN OFFIC
July 17, 2023	S-1/A	As filed with the Securities and Exchange Commission on July 14, 2023 As filed with the Securities and Exchange Commission on July 14, 2023 Registration No.
July 17, 2023	EX-1.1	Form of Underwriting Agreement EXHIBIT 1.1 UNDERWRITING AGREEMENT [●], 2023 Network 1 Financial Securities, Inc. 2 Bridge Ave - Building 2 Suite 241 Red Bank, NJ 07701 As Representative of the several Underwriters named in Schedule I hereto Ladies and Gentlemen: Bionexus Gene Lab Corp., a Wyoming company (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to the s
July 17, 2023	EX-99.2	Audit Committee Charter EXHIBIT 99.2 AUDIT COMMITTEE CHARTER OF BIONEXUS GENE LAB CORP. I. Purpose The purposes of the Audit Committee (the “Audit Committee”) of the Board of Directors (“Board”) of BioNexus Gene Lab Corp., a Wyoming corporation (“Company”) are to assist the Board in monitoring: (1) the integrity of the annual, quarterly, and other financial statements of the Company, (2) the independent auditor’s qualifi
July 17, 2023	EX-99.3	Compensation Committee Charter EXHIBIT 99.3 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF BIONEXUS GENE LAB CORP. I. Purposes The Compensation Committee (the “Committee”) is appointed by the Board of Directors (the “Board”) of BioNexus Gene Lab Corp., a Wyoming corporation (the “Company”) for the purposes of, among other things, (a) discharging the Board’s responsibilities relating to the compensation of th
July 17, 2023	EX-14.1	Code of Business Conduct and Ethics EXHIBIT 14.1 BIONEXUS GENE LAB CORP. Code of Ethics and Business Conduct 1. Introduction. 1.1 The Board of Directors (the “Board”) of BioNexus Gene Lab Corp. (the "Company") has adopted this Code of Ethics and Business Conduct (the "Code") in order to: (a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest; (b) promote full, fair, accurat
July 17, 2023	EX-10.1	Share Exchange Agreement between BioNexus and Chemrex EXHIBIT 10.1
July 17, 2023	EX-99.4	Nomination Committee Charter EXHIBIT 99.4 NOMINATION COMMITTEE CHARTER OF BIONEXUS GENE LAB CORP. The responsibilities and powers of the Nominating Committee (the “Nominating Committee”) of the Board of Directors (“Board”) of BioNexus Gene Lab Corp., a Wyoming corporation (the “Company”), as delegated by the Board, are set forth in this charter. Whenever the Nominating Committee takes an action, it shall exercise its independ
July 5, 2023	EX-4.1	Registrant’s Specimen Certificate for Common Stock EXHIBIT 4.1
July 5, 2023	EX-3.3	Certificate of Amendment filed with the Secretary of the State of Wyoming on June 7, 2017 EXHIBIT 3.3
July 5, 2023	EX-10.3	Employment Agreement with Yee Meng Wong EXHIBIT 10.3 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite II, Avenue 3, Bangsar South City, 8 Jalan Kerinchi 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 Date: August 2, 2022 Ms. Yee Meng Wong, PhD 55, Jalan Prai, Off Jalan Meru Klang, Selangor, Malaysia 41050 Dear Dr. Wong President
July 5, 2023	EX-10.5	Employment Agreement with Wei Li Leong EXHIBIT 10.5 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite, Avenue 3, Bangsar South City, 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 This Executive Employment Agreement (the “Agreement”) is made and entered into as of the 19th day of June, 2017 and will be effectiv
July 5, 2023	EX-3.4	Certificate of Amendment filed with the Secretary of the State of Wyoming on March 29, 2023 EXHIBIT 3.4
July 5, 2023	EX-10.11	Director Offer Letter by and between the Registrant and Chee Keong Yap EXHIBIT 10.11 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia October 1, 2022 Re: Director Offer Letter – Chee Keong Yap Dear Mr. Chee Keong Yap: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background an
July 5, 2023	S-1/A	As filed with the Securities and Exchange Commission on July 3, 2023 As filed with the Securities and Exchange Commission on July 3, 2023 Registration No.
July 5, 2023	EX-FILING FEES	Director Offer Letter by and between the Registrant and Teng Fook Fong EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioNexus Gene Lab Corp.
July 5, 2023	EX-3.5	Certificate of Amendment filed with the Secretary of the State of Wyoming on June 5, 2023 EXHIBIT 3.5
July 5, 2023	EX-10.8	Director Offer Letter by and between the Registrant and Chai Ping Lin EXHIBIT 10.8 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia January 16, 2023 Re: Director Offer Letter – Chai Ping Lin Dear Ms. Chai Ping Lin: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and
July 5, 2023	EX-10.2	Employment Agreement with Yeat Min Fong EXHIBIT 10.2 Bionexus Gene Lab Corporation 203 S Main Street STE 3000, Wyoming 82801 USA Branch: 10-2 Tower B, Vertical Business Suite, Bangsar South, 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia Tel: +60182218762, +6037494076 Date: August 2, 2022 Dr. Yeat Min Fong Lot 16.08, 1 Powerhouse, Persiaran Bandar Utama 47800 Petaling Jaya, Selangor, Malaysia Dear Dr. Fong Chairman/Board Member Thank yo
July 5, 2023	EX-10.9	Director Offer Letter by and between the Registrant and Chak Hua Yew EXHIBIT 10.9 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia October 1, 2022 Re: Director Offer Letter – Chak Hua Yew Dear Mr. Chak Hua Yew: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and exp
July 5, 2023	EX-10.4	Employment Agreement with Sook Keng Yeoh EXHIBIT 10.4 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite II, Avenue 3, Bangsar South City, 8 Jalan Kerinchi 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 Date: July 29, 2022 Mr. Sook Keng Yeoh 40 Jalan TR 3/1, Tropicana Petaling Jaya 47410 Selangor, Malaysia Dear Mr. Yeoh Chief Execu
July 5, 2023	EX-10.7	Director Offer Letter by and between the Registrant and Teng Fook Fong EXHIBIT 10.7 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia October 1, 2022 Re: Director Offer Letter – Teng Fook Fong Dear Mr. Teng Fook Fong: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and
July 5, 2023	EX-10.6	Employment Agreement with Liong Tai Tan EXHIBIT 10.6 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite II, Avenue 3, Bangsar South City, 8 Jalan Kerinchi 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 Date: Nov 27, 2020 Mr Liong Tai Tan 56 Jalan Bakau, Kepong Baru Kuala Lumpur Malaysia Dear Mr Tan Chief Operating Officer/Board Me
July 5, 2023	EX-10.10	Director Offer Letter by and between the Registrant and Boon Teong Teoh EXHIBIT 10.10 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia January 16, 2023 Re: Director Offer Letter – Boon Teong Teoh Dear Mr. Boon Teong Teoh: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background
May 17, 2023	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BioNexus Gene Lab Corp. (Name of Reg
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
May 9, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 9, 2023 As filed with the Securities and Exchange Commission on May 9, 2023 Registration No.
May 9, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioNexus Gene Lab Corp.
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-269753 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
March 10, 2023	DEFR14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BioNexus Gene Lab Corp. (Name of Reg
February 21, 2023	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BioNexus Gene Lab Corp. (Name of Reg
February 14, 2023	EX-21.1	List of Subsidiaries of the Registrant EX-21.1 2 bionex211.htm SUBSIDIARIES EXHIBIT 21.1 Subsidiaries BioNexus Gene Lab Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation
February 14, 2023	S-1	As filed with the Securities and Exchange Commission on February 14, 2023 As filed with the Securities and Exchange Commission on February 14, 2023 Registration No.
February 14, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioNexus Gene Lab Corp.
February 10, 2023	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Bionexus Gene Lab Corp. (Name of Reg
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
August 15, 2022	EX-10.1	Securities Purchase Agreement between the Company and Kevin Wong EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT, made as of this 12th day of April 2022, by and between Keith Wong, (“Purchaser”) with an address located at 7222 E. Doubletree Ranch Rd, Unit 300, Scottsdale, Arizona 85258, USA and Bionexus Gene Lab Corp (“Seller”) with an address located at Tower B, Vertical Business Suite 10-2, No. 8, Jalan Kerinchi, Bangsar South, 59200,
August 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 Bionexus Gene Lab Corp (Exact name of Company as specified in charter) Wyoming 001-37513 47-3709051 (State or other jurisdiction of incorporation) (Commission File No.)
August 15, 2022	EX-10.2	CONSULTING AGREEMENT EX-10.2 3 bionex102.htm CONSULTING AGREEMENT EXHIBIT 10.2 CONSULTING AGREEMENT This Consulting Agreement (the "Agreement") is made and entered into as of Apr 15, 2022 (the "Effective Date"), between BIONEXUS GENE LAB CORP (the "Company"), a corporation registered in Wyoming, located at Tower B, Vertical Business Suite 10-2, No. 8, Jalan Kerinchi, Bangsar South, 59200, Kuala Lumpur, and Keith Wong,
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
April 6, 2022	EX-21	Subsidiaries EX-21 2 bionex21.htm SUBSIDIARIES EXHIBIT 21 Subsidiaries Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation
April 6, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
April 1, 2022	NT 10-K	UNITED STATES NT 10-K 1 bionnt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
May 18, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSACTION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP.
May 17, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 30, 2021	EX-21	Subsidiaries EXHIBIT 21 Subsidiaries Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation
March 30, 2021	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
March 11, 2021	EX-99.1	CHEMREX CORPORATION SDN. BHD. INDEX TO THE AUDITED FINANCIAL STATEMENTS Years Ended December 31, 2019 and 2018 TABLE OF CONTENTS EXHIBIT 99.1 CHEMREX CORPORATION SDN. BHD. INDEX TO THE AUDITED FINANCIAL STATEMENTS Years Ended December 31, 2019 and 2018 TABLE OF CONTENTS Page Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations and Other Comprehensive Income (Loss) 4 Statements of Stockholders’ Equity 5 Statements of Cash Flows 6 Notes to the Financial Statements 7- 13 1 REPORT
March 11, 2021	EX-99.2	CHEMREX CORPORATION SDN. BHD. INDEX TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS 9 MONTHS ENDED SEPTEMBER 30, 2020 TABLE OF CONTENTS EX-99.2 3 bionex992.htm UNAUDITED FINANCIAL STATEMENTS EXHIBIT 99.2 CHEMREX CORPORATION SDN. BHD. INDEX TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS 9 MONTHS ENDED SEPTEMBER 30, 2020 TABLE OF CONTENTS Page Balance Sheets 2 Statements of Operations and Other Comprehensive Income/(Loss) 3 Statements of Stockholders’ Equity 4 Statements of Cash Flows 5 Notes to the Unaudited Financial Statements 6-1
March 11, 2021	8-K/A	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation or organ
March 11, 2021	EX-99.3	BIONEXUS GENE LAB CORP. UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER 30, 2020 EX-99.3 4 bionex993.htm UNAUDITED PRO FORMA FINANCIAL INFORMATION EXHIBIT 99.3 BIONEXUS GENE LAB CORP. UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER 30, 2020 Historical Pro Forma Adjustments Pro Forma BGLC CCSB (Note 3) Combined Assets Current assets: Cash and cash equivalents $ 687,203 $ 1,502,869 $ - $ 2,190,072 Other receivables and deposits 13,847 7,154 - 21,001 Trade re
January 7, 2021	8-K	Changes in Control of Registrant, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commissi
January 7, 2021	EX-3.1	Certificate of Incorporation of Chemrex Sanitary Wares Sdn. Bhd. and Amendment to Chemrex Corporation Sdn. Bhd.(2) EX-3.1 2 bionex31.htm CERTIFICATE OF INCORPORATION EXHIBIT 3.1(d) 1 2
December 30, 2020	EX-10.5	Share Exchange Agreement dated December 24, 2020 by and among BioNexus Gene Lab Corp, a Wyoming company, and Chemrex Corporation Sdn. Bhd., a Malaysian company and the shareholders of the Chemrex. EXHIBIT 10.5 SHARE EXCHANGE AGREEMENT This Agreement ("Agreement") is made and entered into this the 24th day of December 2020 by and between BioNexus Gene Lab Corp, a Wyoming company (the "BioNexus"), and Chemrex Corporation Sdn. Bhd., a Malaysian company ("Chemrex"), and the shareholders of the Chemrex identified on the signatory page of this Agreement (the "Chemrex Shareholders"). * W I T N E S
December 30, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bion8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2020 BIONEXUS GENE LAB CORP . (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction
December 22, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commissi
December 22, 2020	EX-99.1	41 EXHIBIT 99.1 RNA AS A SCREENING TOOL AND BIOMARKER FOR DISEASE: A PARADIGM SHIFT IN MEDICAL RISK STRATIFICATION DR STEPHEN PONNAMPALAM 1 Characteristics of an ideal biomarker DNA vs RNA as biomarker for risk stratification Sentinel principle: its applications for disease detection Epidemiology of disease mortality in Malaysia with a focus on cancer Current biomarkers: drawbacks ColonSentry: a trai
December 10, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2020 BIONEXUS GENE LAB CORP . (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commiss
November 9, 2020	10-Q/A	Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.
November 3, 2020	10-Q	Quarterly Report - FORM 10-Q 10-Q 1 bion10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission Fil
October 8, 2020	EX-16.1	Letter to the Securities and Exchange Commission dated October 1, 2020 from Total Asia Associates PLT.
October 8, 2020	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission
August 11, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
May 8, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
March 31, 2020	EX-21.1	Subsidiaries EXHIBIT 21 Subsidiaries Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation
March 31, 2020	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction ofIncorporation or Organization) (I.
March 30, 2020	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2019 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
November 14, 2019	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSACTION REPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
November 14, 2019	EX-10.5	Agreement For The Development Blood-Based Genomic Signatures In Acute Myocardial Infarction Risk Prediction Research Proposal with Institut Jantung Negara Sdn. Bhd. and Dato Dr. Amin Ariff Bin Nuruddin and Bionexus Gene Lab Sdn Bhd dated August 1, 2019.* EXHIBIT 10.5
October 15, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission
October 15, 2019	EX-10.4	Stock Grant Agreement dated October 1, 2019 by and between the Company and each of Soo Kow Lai, Chi Yuen Leong, Chan Chong Wong and Wei Li Leong. EXHIBIT 10.4 BIONEXUS GENE LAB CORPORATION Stock Grant Agreement Effective Date: October 1, 2019 Grantee: Chan Chong Wong ? Chief Executive Officer (?Grantee?) Name Title Number of shares of Common Stock subject to Grant: 5,000,000 Definitions As used herein the following words and phrases shall have the meanings ascribed thereto. ?Business Relationship with the Company? means the officer/employer
August 9, 2019	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSACTION REPORT PUR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ? TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
May 15, 2019	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSACTION REPORT PU Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I.
April 2, 2019	CORRESP	BIONEXUS GENE LAB CORP. Level 8, Tower 8, Avenue 5, The Horizon Bangar South No. 8 Jalan Kerinchi 59200 Kuala Lumpur BIONEXUS GENE LAB CORP. Level 8, Tower 8, Avenue 5, The Horizon Bangar South No. 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia April 2, 2016 Via EDGAR SECURITIES AND EXCHANGE COMMISSION Securities and Exchange Commission Attn: Mr. Ruairi Regan Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation File No. 333-229399 Dear Mr. Regan: BioNexus Gene Lab Corporation hereby
April 2, 2019	CORRESP	BIONEXUS GENE LAB CORP. Level 8, Tower 8, Avenue 5, The Horizon Bangar South No. 8 Jalan Kerinchi 59200 Kuala Lumpur CORRESP 1 filename1.htm BIONEXUS GENE LAB CORP. Level 8, Tower 8, Avenue 5, The Horizon Bangar South No. 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia April 2, 2019 Via EDGAR SECURITIES AND EXCHANGE COMMISSION Securities and Exchange Commission Attn: Mr. Ruairi Regan Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation File No. 333-229399 Dear Mr. Regan: BioNexus Gene
March 27, 2019	CORRESP	1 March 26, 2019 Securities and Exchange Commission Attn: Mr. Ruairi Regan Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation Amendment No. 1 to Registration Statement on Form S-1 Filed February 25, 2019 File No. 333-229399 Dear Mr. Regan: On behalf of our client, BioNexus Gene Lab Corporation, a Wyoming corporation (the “Company”), we are filing herewith an Amendmen
March 27, 2019	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 807101 35- S-1/A 1 a-2vedgar2.htm As filed with the Securities and Exchange Commission on March 27 , 2019 Registration No. 333-229399 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 807101 35-2604830 (State or other jur
February 25, 2019	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 807101 35- As filed with the Securities and Exchange Commission on February , 2019 Registration No.
February 25, 2019	CORRESP	February 25, 2019 Converted by EDGARwiz February 25, 2019 Securities and Exchange Commission Attn: Mr.
January 29, 2019	EX-3	Articles of Association of PE Furnishings Sdn. Bhd, Name Change to BGS Lab Sdn. Bdh and Name Change to BioNexus Gene Lab Sdn. Bdh(1)
January 29, 2019	EX-10	Securities and Laboratory Equipment/Stock/Technical Know-How Exchange Agreement between BGS Lab Sdn Bhd and Dr. Liew Choong Chin(1)
January 29, 2019	EX-3	Bylaws of the Registrant(1) Converted by EDGARwiz BYLAWS OF BIO NEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require. Section 1
January 29, 2019	EX-10	Waiver of Dr. Liew(1) LIEW CHOONG-CHIN 81 Millersgrove Dr. Toronto M2R 3S1 ON Canada Date: 15.2.2018 The Board of Directors Bionexus Gene Lab SDN. BHD. 20-12 Camellia,5 Jalan Kerinchi . Bangsar South Kuala Lumpur Dear Sirs, Re: WAIVER OF LIABILITIES I, Liew Choong-Chin (Passport No. GK429314), a shareholder of Bionexus Gene Lab Sdn Bhd, hereby confirmed and agreed on this date to waive all the money owing by Bionexus G
January 29, 2019	S-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 807101 35-2604830 (State o S-1 1 final1-23-19vedgar4.htm As filed with the Securities and Exchange Commission on , 2019 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 807101 35-2604830 (State or other jurisdiction of incorporation or
January 29, 2019	EX-10	Stock Exchange Agreement between the Registrant and BGS Lab Sdn. Bbh. and its shareholders dated August 23, 2017(1)
January 29, 2019	EX-3	Articles of Amendment of Registrant(1) Converted by EDGARwiz
January 29, 2019	EX-3	Articles of Incorporation of the Registrant, as currently in effect Converted by EDGARwiz Wyoming Secretary of State 2020 Carey Avenue Suite 700 Cheyenne, WY 82002-0020 Ph.

BGLC / BioNexus Gene Lab Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)